在医疗行业IPO活跃的大环境下,Metsera Inc. (MTSR)于今日在美国纳斯达克成功上市,公司股价盘中大涨41.67%,引起了市场广泛关注。
据报道,Metsera是一家临床阶段的生物技术公司,正在开发基于GLP-1机制和其他生物靶点的注射和口服药物来治疗肥胖症及相关疾病。在此次IPO中,公司以每股18美元的发行价共发行了1528万股,募资总额高达2.75亿美元。以发行价计算,Metsera的估值约为18.5亿美元。
Metsera此前已从多家知名投资机构获得融资支持,包括ARCH Venture Partners、Population Health Partners、Fidelity Investments、Mubadala Capital等。IPO后,这些机构将继续持有Metsera股权。分析人士认为,成功上市筹得的资金将为公司后续新药研发和商业化提供重要支持,增强了市场对其长期发展前景的信心。另外,同期还有药企Maze Therapeutics赴美上市,可能也对医疗生物行业形成提振。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.